EUVIMEDEUVIMED entdecken
Kohortenstudie

The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Oras A Alabas iD, Kayleigh J Mason iD, Zenas Z N Yiu iD, Richard B Warren iD, Nick Dand iD, Jonathan N Barker, Catherine H Smith, Christopher E M Griffiths, BADBIR and BSTOP study group

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljad481 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Oras A Alabas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Centre, Northern Care Alliance NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Tru…. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: British Association of Dermatologists Biologic Register Ltd, National Institute for Health and Care Research, Medical Research Council Stratified Medicine award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few studies have used real-world data to investigate the association between biologic therapy survival and age at psoriasis onset or HLA-C*06:02 status in patients with moderate-to-severe psoriasis. The robustness of these studies is limited by small sample size, short follow-up and diverse safety and effectiveness measures.

Objectives

To describe biologic survival and explore whether the response to biologics is modified by age at psoriasis onset or HLA-C*06:02 status in patients with moderate-to-severe psoriasis.

Methods

Data from patients in the UK and the Republic of Ireland registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from 2007 to 2022 on a first course of adalimumab, etanercept, secukinumab or ustekinumab with at least 6 months’ follow-up and a subset of BADBIR patients with available HLA-C*06:02 information registered to Biomarkers and Stratification To Optimise outcomes in Psoriasis (BSTOP) were analysed. Patients aged ≥ 50 years at treatment initiation were classified into early-onset psoriasis (EOP) (presenting in patients ≤ 40 years of age) and late-onset psoriasis (LOP) (presenting in patients > 40 years of age). BADBIR patients with available information in BSTOP were categorized as HLA-C*06:02− or HLA-C*06:02 + . Biologic survival was defined as treatment discontinuation associated with ineffectiveness or occurrence of adverse events (AEs). Adjusted survival function and hazard ratio (aHR) with 95% confidence interval (CI) were estimated using a flexible parametric model to compare discontinuing therapy between age at psoriasis onset and HLA-C*06:02 groups. Each model included exposure (biologics), effect modifier (age at onset or HLA-C*06:02 status), interaction terms and several baseline demographic, clinical and disease severity covariates.

Results

Final analytical cohorts included 4250 patients in the age at psoriasis onset group [2929 EOP (69%) vs. 1321 LOP (31%)] and 3094 patients in the HLA-C*06:02 status group [1603 HLA-C*06:02+ (52%) vs. 1491 HLA-C*06:02− (48%)]. There was no significant difference between EOP and LOP in drug survival associated with ineffectiveness or AEs for any biologics. However, compared with patients who were HLA-C*06:02−, patients who were HLA-C*06:02 + were less likely to discontinue ustekinumab for reasons associated with ineffectiveness (aHR 0.56, 95% CI 0.42–0.75).

Conclusions

HLA-C*06:02, but not age at psoriasis onset, is a predictive biomarker for biologic survival in patients with psoriasis. Findings from this large cohort provide further, important information to aid clinicians using biologic therapies to manage patients with psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsHumansAdultCohort StudiesUstekinumabHLA-C AntigensDermatologistsRegistriesBiological FactorsAdalimumabEtanerceptImmunologic FactorsAdjuvants, ImmunologicTreatment Outcome

Substanzen

UstekinumabHLA-C AntigensBiological FactorsAdalimumabEtanerceptImmunologic FactorsAdjuvants, ImmunologicBiological Products

Autor:innen und Institutionen

  • Dermatology Centre, Northern Care Alliance NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, University of Mancheste…
  • Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK.
  • Department of Medical and Molecular Genetics, School of Basic & Medical Biosciences, King's College London, UK.
  • St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.

ORCID-Profile: Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, Richard B Warren, Nick Dand

Förderung

  • British Association of Dermatologists Biologic Register Ltd
  • National Institute for Health and Care Research
  • Medical Research Council Stratified Medicine award
  • National Institute for Health Research Biomedical Research Centre

Zitieren

APA

Alabas, O. A., Mason, K. J., Yiu, Z. Z. N., Warren, R. B., Dand, N., Barker, J. N., Smith, C. H., Griffiths, C. E. M., & BADBIR and BSTOP study group (2024). The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad481

Vancouver

Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Dand N, Barker JN, et al. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2024. doi:10.1093/bjd/ljad481

BibTeX
@article{Alabas2024,
  author = {Alabas, Oras A and Mason, Kayleigh J and Yiu, Zenas Z N and Warren, Richard B and Dand, Nick and Barker, Jonathan N and Smith, Catherine H and Griffiths, Christopher E M and BADBIR and BSTOP study group, BADBIR and BSTOP study group},
  title = {The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljad481}
}
Kostenlos starten →